Immune-cold solid tumors were found to exhibit molecular characteristics associated with homologous recombination deficiency (HRD), revealing potential therapeutic vulnerabilities in cancers that typically show poor response to immunotherapy.
HRD-related defects in DNA damage repair pathways contribute to increased genomic instability, which may influence tumor biology and immune microenvironment dynamics.
Tumors harboring HRD signatures may demonstrate enhanced sensitivity to PARP inhibitors, which target DNA repair mechanisms and exploit synthetic lethality in HRD-positive cancers.
HRD-associated genomic instability may also create opportunities for combination treatment strategies, including PARP inhibitors alongside immune checkpoint inhibitors.
These findings suggest that DNA repair pathway alterations could serve as predictive biomarkers for identifying patients who may benefit from targeted therapeutic approaches.
Understanding the relationship between HRD status and immune-cold tumor microenvironments may help overcome resistance to current immunotherapy treatments.
Integrating HRD biomarker analysis into precision oncology workflows could improve patient stratification and guide personalized treatment strategies.
Overall, targeting homologous recombination deficiency in immune-cold tumors may open new avenues for therapeutic intervention in malignancies that currently have limited treatment options.
Read Abstract